The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: What do we know regarding its pharmacokinetics?

Nelson Leung; Thomas E. Witzig

doi:10.3109/10428194.2013.809530

The use of ⁹⁰yttrium-ibritumomab tiuxetan in patients on dialysis: What do we know regarding its pharmacokinetics?

Nelson Leung, Thomas E. Witzig

Hematology

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	2586-2587
Number of pages	2
Journal	Leukemia and Lymphoma
Volume	54
Issue number	12
DOIs	https://doi.org/10.3109/10428194.2013.809530
State	Published - Dec 1 2013

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2013.809530

Cite this

@article{d066db037443416cad49b387bbc1ee8f,

title = "The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: What do we know regarding its pharmacokinetics?",

author = "Nelson Leung and Witzig, {Thomas E.}",

year = "2013",

month = dec,

day = "1",

doi = "10.3109/10428194.2013.809530",

language = "English (US)",

volume = "54",

pages = "2586--2587",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "12",

}

TY - JOUR

T1 - The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis

T2 - What do we know regarding its pharmacokinetics?

AU - Leung, Nelson

AU - Witzig, Thomas E.

PY - 2013/12/1

Y1 - 2013/12/1

UR - http://www.scopus.com/inward/record.url?scp=84887226511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887226511&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.809530

DO - 10.3109/10428194.2013.809530

M3 - Comment/debate

C2 - 23734658

AN - SCOPUS:84887226511

SN - 1042-8194

VL - 54

SP - 2586

EP - 2587

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -

The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: What do we know regarding its pharmacokinetics?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

The use of ⁹⁰yttrium-ibritumomab tiuxetan in patients on dialysis: What do we know regarding its pharmacokinetics?